Safety data were also deemed positive for the drug. A pre-specified interim analysis of the trial, presented at the 2023 American Society of Clinical Oncology Annual Meeting, was conducted based on a total of 92 participants. Of these patients, 63% developed any-grade cytokine release syndrome (CRS), at a median of 9 days post-infusion and a median duration of 5 days. Additionally, any grade immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in 23% of patients.3
About the Trial
Trial Name: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
ClinicalTrials.gov ID: NCT04404660
Estimated Completion Date: May 2025
More detailed safety data were released by the FDA, with the agency noting that the prescribing information for obecabtagene autoleucel contains a boxed warning for CRS, ICANS, and T-cell malignancies. In the full study population, CRS occurred in 75% of participants, with neurological toxicities occurring in. 64%, including ICANS in 24%.1
Common non-laboratory adverse reactions—with an incidence of ≥ 20%--included CRS, pathogen-unspecified musculoskeletal pain, viral infections, nausea, fever, diarrhea, febrile neutropenia, ICANS, and headache, among others. In the interim analysis, febrile neutropenia was also observed, at a rate of 25%, in addition to anemia (20%).1,3
In their announcement, the FDA wrote that the recommended dose of obecabtagene autoleucel is 410 X 106 CD19 chimeric antigen receptor (CAR)-positive viable T cells to be administered as split dose infusion on Day 1 and Day 10. The dose should be based on bone marrow blast assessment and follow fludarabine and cyclophosphamide lymphodepleting chemotherapy.1
REFERENCES
1. FDA. FDA obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. News Release. Released November 8, 2024. Accessed November 11, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute#:~:text=On%20November%208%2C%202024%2C%20the,acute%20lymphoblastic%20leukemia%20(ALL).
2. National Library of Medicine. A study of CD19 targeted CAR T cell therapy in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL). ClinicalTrials.gov. Last updated September 3, 2024. Accessed November 11, 2024. https://clinicaltrials.gov/study/NCT04404660
3. Roddie C, Sandhu KS, Tholouli E, et al. Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study. J Clin Oncology. 2023;41(16). doi:10.1200/JCO.2023.41.16_suppl.7000